Fulcrum Therapeutics | Sustainability Performance
Engages in the discovery and development of therapies targeting the regulation of gene expression.
2016
United States
51 - 200 employees
Biotechnology
$25M - 100M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#6388
Overall#1410
in United States#123
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$80.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
R&D intensity
78.8%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-4.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 20.0%
0.0
▼ 15.4%
0.1
▼ 2.5%
0.3
2031Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
73%
Independent Directors
8 out of 11 incl. management
Overall score
69
Environment
74
Social
76
Governance
56
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
